Expanding the medical-related business and establishing a structure capable of pursuing a stock market listing
First written in FY2016. 7 of 15 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3Cited as achievedAnnual report
「In connection with 株式会社ステムセル研究所's listing on the Tokyo Stock Exchange Mothers market on 25 June 2021, we issued new shares through a public offering and sold part of the company's shares held by 株式会社トリムメディカルホールディングス, another consolidated subsidiary of ours.」
The listing of ステムセル研究所 and the diversification of fundraising methods through a public offering and the partial sale of shares held are cited as achievements. - FY2022-Q1AchievedAnnual report
「In the regenerative medicine-related business, ステムセル研究所 listed on the TSE Mothers market on 25 June this year.」
For group company ステムセル研究所, which had been aiming to list its medical-related business, the planned listing on the TSE Mothers market on 25 June was completed. - FY2021AdvancedAnnual report
「For ステムセル研究所, which operates a cell banking business, approval was obtained on 21 May this year for a listing on the Tokyo Stock Exchange Mothers market, with the listing scheduled for 25 June. Going forward, market-based fundraising will also become an option.」
ステムセル研究所 advanced to the stage of obtaining approval for a listing on the Tokyo Stock Exchange Mothers market and announcing a scheduled listing date of 25 June. - FY2021-Q3AdvancedAnnual report
「The company reapplied for a listing on the Tokyo Stock Exchange on 8 December 2020.」
Following the listing postponement, ステムセル研究所 advanced to the stage of reapplying for a listing on the Tokyo Stock Exchange on 8 December 2020. - FY2021-Q2RaisedAnnual report
「Although the company obtained approval in March this year for a new listing on the Tokyo Stock Exchange, it postponed the listing after comprehensively considering trends in the IPO market arising from the COVID-19 pandemic and other factors, and is aiming to list within the current fiscal year after further enhancing corporate value.」
Following the postponement, the wording became more specific, changing from “considering a listing at an appropriate time” to “aiming to list within the current fiscal year.” - FY2021-Q1SoftenedAnnual report
「Although the company obtained approval in March this year for a new listing on the Tokyo Stock Exchange, it postponed the listing after comprehensively considering trends in the IPO market arising from the COVID-19 pandemic and other factors, and is considering a listing at an appropriate time after further enhancing corporate value.」
While ステムセル研究所 advanced to the stage of obtaining approval for a new listing on the Tokyo Stock Exchange, it postponed the listing in light of the COVID-19 pandemic and IPO market conditions, and the wording now indicates that an appropriate time is being reconsidered. - FY2020-Q3AdvancedAnnual report
「In the regenerative medicine field, 株式会社ステムセル研究所, which operates a cord blood storage business, applied for a listing on the Tokyo Stock Exchange on 6 January this year.」
As part of the drive to list the medical-related business, the process advanced to the specific stage of group company ステムセル研究所 applying for a listing on the Tokyo Stock Exchange, rather than the holding company itself completing a listing. - FY2019-Q1RaisedAnnual report
「株式会社トリムメディカルホールディングス, a strategic holding company in the advanced medical field, is developing its business with the aim of listing in the near future.」
Regarding the listing, the wording has become more explicit about the goal, changing from the previous “preparations are being advanced with a listing in mind” to “developing the business with the aim of listing in the near future.” - FY2018SoftenedAnnual report
「株式会社トリムメディカル ホールディングス is actively expanding its business, including launching new businesses and pursuing M&A, and is advancing preparations with a listing in mind as a step toward further growth in the future.」
Regarding the listing, the wording has changed from the previous “preparations are under way for a listing” to “preparations are being advanced with a listing in mind.” - FY2018-Q3AdvancedAnnual report
「In the advanced medical-related business, together with 株式会社ステムセル研究所, ヒューマンライフコード株式会社, which aims to develop domestically produced cell-based pharmaceuticals, and ストレックス株式会社, which manufactures and sells equipment related to regenerative medicine, we are preparing for a listing, centered on the holding company 株式会社トリムメディカル ホールディングス, with the aim of making regenerative medicine and cell therapy one of the pillars of the future Nippon Trim Group.」
It was explicitly stated that preparations for a listing are under way, centered on the holding company and the 3 related companies, with the aim of making regenerative medicine and cell therapy a pillar of the group. - FY2017AdvancedAnnual report
「株式会社トリムメディカル ホールディングス, a strategic holding company in the advanced medical field, is currently working to strengthen its business foundation in regenerative and restorative medicine and reproductive medicine (fertility treatment), areas expected to see substantial market expansion going forward. …In April this year, we established a new company, 「ヒューマンライフコード株式会社」, to develop pharmaceutical products from cells derived from human tissues such as placentas and umbilical cords.」
Progress is being made toward building a business foundation in cell-based pharmaceuticals through the establishment of ヒューマンライフコード, in addition to regenerative and restorative medicine and reproductive medicine. - FY2017-Q3AdvancedAnnual report
「To further stabilize our management foundation in the medical field, we acquired additional shares held by non-controlling shareholders and made ㈱トリムメディカル ホールディングス a wholly owned subsidiary.」
Made トリムメディカル ホールディングス a wholly owned subsidiary to stabilize the management foundation of the medical-related business. - FY2017-Q2AdvancedAnnual report
「To further stabilize the management foundation in the medical field, we acquired a portion of the shares held by non-controlling shareholders.」
The company acquired additional shares in a consolidated subsidiary from non-controlling shareholders to strengthen its management foundation in the medical field. - FY2017-Q1RestatedAnnual report
「To achieve sustainable growth in the future, the Group will accelerate the expansion of new business areas, including agriculture and healthcare, in addition to its water ionizer sales business, while also focusing on expanding in advanced medicine, thereby advancing from a home medical equipment manufacturer to a medical company.」
The company has continued to refer to expanding its advanced medical services business. This disclosure does not indicate specific progress toward establishing a framework for pursuing a listing. - FY2016First statedAnnual report
「㈱トリムメディカル ホールディングス, the holding company overseeing the advanced medical services business, is entering the hospital operations business in China to expand its operations. Going forward, it is developing a global medical-related business centered on regenerative medicine and building a platform capable of pursuing business expansion and a future listing.」
The company aims to develop a global medical business centered on regenerative medicine and has established a framework capable of pursuing a future listing.